Highlights

  • Sofdra prescriptions shipped increased 25% to 33,358 during Q4 FY26, including a monthly record of 12,895 in June.
  • Unaudited Sofdra net revenue rose 45% to US$10.1 million as quarterly gross sales reached US$46.7 million.
  • Operating cash outflow declined 54% to US$10.6 million, supported by higher sales receipts and lower manufacturing payments.
  • Botanix ended June with US$36.6 million in cash after receiving US$30.1 million from its capital raising activities.
  • BOT traded at AUD 0.022 during morning trade on 27 July 2026 and remained 87.06% lower over the past year.

Botanix Pharmaceuticals Limited (ASX:BOT) reported further commercial progress for Sofdra during the June 2026 quarter, with prescriptions shipped increasing 25%, unaudited net revenue rising 45% and operating cash outflow falling by more than half compared with the previous quarter. The clinical dermatology company also outlined plans to reduce operating costs through sales force restructuring while continuing to expand its intellectual property and supply chain arrangements.

Botanix shares traded at AUD 0.022 during the morning session on 27 July 2026, with the supplied market data showing a 4.35% movement for the session. The stock remains down 87.06% over the past year, representing a decline of AUD 0.15 across the 12-month period.

The quarterly report covers the three months ended 30 June 2026 and captures the continued commercial rollout of Sofdra, Botanix’s FDA-approved treatment for primary axillary hyperhidrosis. Management said prescription and sales trends continued to improve across several key operating measures during the period.

Sofdra Prescription Shipments Increase 25%

Total Sofdra prescriptions shipped rose to 33,358 in Q4 FY26 from 26,684 in the March quarter, representing quarterly growth of 25%.

The June quarter followed slower prescription growth during January and February, when winter conditions in the United States affected demand. Shipment momentum subsequently improved in March and continued through the final quarter of FY26.

June 2026 delivered a new monthly shipment record, with 12,895 prescriptions shipped during the month.

The result indicates that monthly volumes continued to increase as Botanix expanded the commercial launch and more patients accessed the product.

Management said it was pleased with the sales trajectory and remained confident in the continuation of Sofdra’s commercial momentum.

Quarterly Net Revenue Climbs to US$10.1 Million

Sofdra generated gross sales of US$46.7 million during the June quarter, compared with US$38.0 million in Q3 FY26.

Unaudited net revenue attributable to Botanix increased to US$10.1 million from US$6.9 million in the previous quarter. This represented quarter-on-quarter growth of approximately 45%.

The increase in net revenue was higher than the 23% rise in gross sales, reflecting an improvement in Botanix’s average gross-to-net yield.

Gross-to-net yield measures the percentage of gross sales retained as net revenue after accounting for deductions such as rebates, discounts, patient assistance and other commercial adjustments.

Botanix reported an average gross-to-net yield of 22% for Q4 FY26, compared with 18% in the March quarter.

The company expects the yield to continue improving during the first quarter of FY27.

Insurance Deductible Conditions Begin to Normalise

The improvement in gross-to-net yield followed the annual reset of US healthcare insurance deductibles at the beginning of the calendar year.

Botanix said the reset affected approximately half of privately insured Americans under the age of 65 and placed pressure on net revenue during the March quarter.

At the start of each year, patients covered by high-deductible insurance plans may be required to pay more of their healthcare expenses before insurance coverage increases.

As deductibles are met during the year, product reimbursement conditions may improve. Botanix said this normalisation contributed to the increase in its average gross-to-net yield from 18% to 22%.

Management expects this recovery trend to continue into Q1 FY27, which may support further improvement in the amount of gross Sofdra sales converted into net revenue.

Operating Cash Outflow Falls 54%

Net cash used in operating activities declined to US$10.6 million during Q4 FY26 from US$23.3 million in Q3 FY26.

The reduction of approximately 54% was driven by increased product sales receipts and lower product manufacturing payments.

Receipts from product sales, net of deductions, totalled US$13.4 million during the quarter, while royalty receipts contributed a further US$0.2 million.

Botanix made US$6.4 million in payments relating to gross-to-net deductions from product sales.

Product manufacturing payments fell to US$1.2 million from US$11.0 million in the previous quarter.

The reduction primarily reflected the deferral of a US$9.7 million active pharmaceutical ingredient purchase that had previously been due in April 2026. Botanix renegotiated the timing of that purchase into future years while maintaining sufficient inventory to support anticipated growth.

This helped reduce near-term cash requirements and improve working capital flexibility.

Operating Costs Decline as Management Maintains Cost Controls

Botanix reported operating costs of US$11.5 million for the quarter, down approximately 10% from the previous period.

Management attributed the reduction to lower overall operating expenses and said underlying spending remained aligned with its cost-control strategy.

Staff costs totalled US$2.7 million during the quarter, while general and administrative payments were US$1.7 million.

Royalty payments amounted to US$0.5 million, and interest payments totalled US$0.5 million.

For the full financial year, Botanix used US$64.3 million in operating activities. This included product manufacturing payments of US$17.1 million, operating costs of US$49.2 million and staff costs of US$13.4 million.

The company generated US$44.8 million in product sales receipts, net of deductions, during FY26.

Sales Force Restructuring Targets 12% Cost Reduction

Botanix is completing a sales force sizing and territory alignment initiative designed to improve commercial efficiency.

The company said 90% of Sofdra prescriptions are currently generated across 39 of its 50 sales territories.

Botanix plans to reallocate the most valuable physician targets from 11 unprofitable territories to the 39 higher-performing territories.

The restructuring is expected to maintain approximately 94% coverage of targeted healthcare providers while reducing the sales force by 11 positions.

The changes are scheduled to begin on 31 July 2026 and are expected to lower overall operating costs by approximately 12%.

The initiative is intended to concentrate commercial resources in territories producing most of the current prescription volume while preserving access to the physicians considered most valuable to Sofdra’s growth.

Botanix said the changes form part of its wider focus on profitability, return on investment and disciplined resource allocation.

Cash Position Rises to US$36.6 Million

Botanix ended the June quarter with US$36.6 million in cash, compared with US$22.1 million at the end of the previous quarter.

The increase was supported by the receipt of US$30.1 million before costs from the remaining portion of the company’s US$45.0 million capital raising.

The second tranche of the placement settled on 13 April 2026 and raised US$25.1 million before costs.

A securities purchase plan settled on 20 April 2026, raising another US$5.0 million before costs.

Transaction costs associated with equity issues totalled US$2.4 million during the quarter.

Botanix also repaid US$2.8 million in borrowings and made US$0.1 million in payments relating to right-of-use assets.

Net cash generated from financing activities reached US$24.8 million for the quarter.

After accounting for operating cash outflow, financing activities and foreign exchange movements, the company’s cash balance increased by US$14.5 million during the period.

Available Funding Estimated at US$51.2 Million

Botanix reported total loan facilities of US$40.9 million at the end of the quarter, of which US$26.3 million had been drawn.

The facility is provided by Kreos Capital VII and allows Botanix to borrow up to the euro equivalent of US$30.0 million.

Tranche A of US$20.0 million was drawn in June 2025. A further US$10.0 million Tranche B may be available for drawdown until 1 October 2026, subject to specified conditions.

The secured facility carries annual interest of 9.95%.

Tranche A matures on 1 October 2028, while Tranche B would mature on 1 July 2029.

Botanix disclosed US$14.6 million of unused financing facilities in its Appendix 4C, although it noted that the second tranche was not available for drawdown at 30 June 2026 because the required conditions had not been satisfied at that date.

Combining its quarter-end cash balance and unused facilities, Botanix reported available funding of approximately US$51.2 million.

Based on the June quarter operating cash outflow, the company estimated that this funding represented approximately 4.82 quarters of operating coverage.

Alternative API Supplier Could Support Future Margins

Botanix is progressing the onboarding of Piramal as an alternative supplier of the active pharmaceutical ingredient used in Sofdra.

The company expects the additional supplier to improve supply chain resilience, increase manufacturing flexibility and reduce the long-term cost of goods sold.

Onboarding has commenced and is expected to be completed during 2028.

Introducing a second source may reduce the company’s dependence on a single supplier and provide greater flexibility when ordering materials to support future demand.

The initiative forms part of Botanix’s broader plan to improve gross margins and optimise working capital as Sofdra prescription volumes increase.

Botanix also highlighted its successful renegotiation of the existing API supply agreement, which allowed the US$9.7 million payment originally scheduled for April 2026 to be deferred into future years.

Patent Developments Extend Sofdra Protection Strategy

During July, Botanix received an Intention to Grant relating to a European patent application covering the Sofdra applicator.

The company also received a Notice of Allowance for a US patent application covering the Sofdra drug substance.

These applications add to existing patents and pending protections associated with the product.

Botanix said its intellectual property portfolio may provide protection for the Sofdra franchise into 2040.

The company considers the expanded patent estate important for supporting future commercialisation, licensing and potential acquisition discussions.

A longer period of patent protection may help preserve the product’s commercial position by restricting direct competition involving protected formulations, substances or delivery methods.

Botanix Reviews Licensing and Acquisition Opportunities

The company said FY26 represented an important commercial year following the launch and continued growth of Sofdra.

Alongside prescription growth, Botanix is evaluating strategic opportunities that may make use of its existing commercial infrastructure, fulfilment platform and patient service capabilities.

Management said the company has received inbound interest relating to possible licensing and acquisition transactions.

Botanix is considering opportunities that could add products to its commercial platform and improve the use of its existing resources.

The company believes its fulfilment capabilities can be expanded to support additional products beyond Sofdra.

Its stated areas of focus include increasing Sofdra sales, improving cash flow performance, strengthening intellectual property, reducing costs, onboarding a second API supplier and evaluating strategic transactions.

Botanix did not disclose specific counterparties or transaction terms associated with the inbound interest.

Chief Operating Officer Appointment Expands Management Capacity

During the quarter, Botanix promoted Paul Seaback from Chief Technical Officer to Chief Operating Officer.

In the expanded position, Mr Seaback will oversee day-to-day operations, manage strategic initiatives and support operating efficiencies across the business.

He joined Botanix as Chief Technical Officer in November 2024 and was responsible for areas including chemistry, manufacturing and controls, supply, quality, regulatory matters, pharmacovigilance, medical affairs and technical services.

Mr Seaback has more than 30 years of biopharmaceutical industry experience.

Before joining Botanix, he served as Chief Technical Officer at Dermavant Sciences until that company was acquired by Organon.

His previous experience also includes leadership roles at Gilead, Medicis, Hospira, Mayne and Novartis subsidiary Sandoz.

The promotion comes as Botanix moves from the initial launch phase of Sofdra toward a greater focus on operational efficiency, supply chain management and commercial scalability.

Employee Performance Rights Convert Into Shares

A total of 14.21 million performance rights were exercised by employees during the June quarter.

This included seven million performance rights exercised by Chief Executive Officer Howard McKibbon and 750,000 exercised by US Chief Financial Officer Chris Lesovitz.

The performance rights carried a nil exercise price and resulted in Botanix issuing 14.21 million fully paid ordinary shares.

Shareholders also approved the placement and securities purchase plan resolutions considered at the Extraordinary General Meeting held on 1 April 2026.

Botanix reported payments of approximately US$0.69 million to directors and executive personnel during the quarter. These payments related to services provided under employment, consulting and director arrangements.

Several options and performance rights were also cancelled during the period because of expiry or the lapsing of conditional entitlements.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is a Phoenix-based dermatology company focused on developing and commercialising treatments for skin conditions.

Its principal commercial product is Sofdra, or sofpironium topical gel 12.45%, which has received approval from the US Food and Drug Administration for the treatment of primary axillary hyperhidrosis.

Primary axillary hyperhidrosis is characterised by excessive underarm sweating and can affect patients’ daily activities, social interactions and quality of life.

According to Botanix, Sofdra is the first and only new chemical entity approved by the FDA for this condition.

The company has established a US commercial platform that includes sales, patient services and product fulfilment capabilities.

Botanix intends to use this infrastructure to increase Sofdra prescriptions while potentially supporting other dermatology products through licensing, acquisition or partnership arrangements.

What This Means for Investors

Botanix’s June quarter report showed improvement across Sofdra prescription shipments, gross sales, unaudited net revenue and operating cash flow.

Quarterly prescriptions increased 25%, while net revenue advanced 45% as the average gross-to-net yield recovered to 22%. Operating cash outflow fell by 54%, although Botanix continued to use US$10.6 million in operations during the period.

The company’s US$36.6 million cash balance was supported by the capital raise rather than operating cash generation. Botanix therefore remains focused on reducing expenses and moving the Sofdra business toward improved profitability.

The planned reduction of 11 sales territories is expected to lower operating costs by approximately 12% while maintaining 94% coverage. Further improvement will depend on continued prescription growth, higher net revenue yields, disciplined spending and progress toward sustainable commercial cash flow.